January 29, 2016 – 11:42 pm
Jeffrey Shuren, M.D., J.D., the Director of the Center for Device and Radiological Health at the Food and Drug Administration, replied to an open letter from the Leiomyoma Morcellation Review Group. You can read the original open letter here, and view Dr. Shuren’s reply in the images below. The Leiomyoma Morcellation Review Group sent the […]
By webmaster
|
Posted in Recent Fibroid Research
|
Also tagged abdominal myomectomy, FDA, fibroid surgery, fibroids, Food and Drug Administration, laparoscopic myomectomy, laparoscopy, leiomyosarcoma, LMS, Morcellation, morcellation and cancer, morcellation risks, morcellator, ovarian cancer, power morcellation
|
December 8, 2015 – 5:00 pm
In November, 2014 the FDA ruled that power morcellation was contra-indicated in “the majority of women” having surgery for uterine fibroids due to the potential risk of spreading occult uterine sarcoma. Although problems with this ruling were immediately apparent, the passage of time has allowed for more clarity on the related medical issues. Prevalence of […]
By webmaster
|
Posted in Recent Fibroid Research
|
Also tagged abdominal myomectomy, FDA, fibroid surgery, fibroids, Food and Drug Administration, laparoscopic myomectomy, laparoscopy, leiomyosarcoma, LMS, Morcellation, morcellation and cancer, morcellation risks, morcellator, no hysterectomy, ovarian cancer, power morcellation
|
August 19, 2014 – 10:01 am
Some people have recently suggested that all women have biopsies of their fibroids before surgery to determine which women have typical fibroids and which women might have a leiomyosarcoma (LMS). There are many problems with this idea. To start, I am going to use the word tumor throughout this post. When we hear” tumor”, most […]
Disclaimer: The ideas, procedures and suggestions contained on this web site are not intended as a substitute for consulting with your physician. All matters regarding your health require medical supervision.